Skip To Main Content
Omar Kabbarah on Muck Rack

Omar Kabbarah

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Omar

Contact Omar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

|
By Toni K. Choueiri, Jaime R. Merchan, Amita Patnaik, Alexandra Drakaki, Brian Rini Verified, Sun Young Rha, Jae Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Yusra Shao, Pedro Barata, Bradley A McGregor, Paul Foster, Jianfen Chen, Melissa Eisen, Hunter Cole, Ben Weeder, Yinghui Guan, Jaskirat Singh, Angelo Kaplan, Soonweng Cho, Richard Markus, Omar Kabbarah, Rana R. McKay
| Nature Verified
Correction to: Nature https://doi.org/10.1038/s41586-026-10718-x Published online 1 July 2026 In the version of this article initially published, the name of Jaime Merchán was misspelled (Jamie Merchan) and is now amended in the HTML and PDF versions of the article.
Open in Who Shared Issue with article?

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

|
By Toni K. Choueiri, Amita Patnaik, Alexandra Drakaki, Brian Rini Verified, Sun Young Rha, Jae Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Pedro Barata, Bradley A McGregor, Paul Foster Verified, Jianfen Chen, Melissa Eisen, Hunter Cole, Ben Weeder, Yinghui Guan, Jaskirat Singh, Angelo Kaplan, Soonweng Cho, Richard Markus, Omar Kabbarah, Rana R. McKay, Jamie Merchan, Yusra Shao
| Nature Verified
Abstract Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor 2α (HIF-2α)1. Here we show that monotherapy with casdatifan—an orally bioavailable, potent and selective HIF-2α inhibitor2—produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC.
Open in Who Shared Issue with article?

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

|
By Zev A. Wainberg, Gulam A. Manji, Nathan Bahary, Susanna V Ulahannan, Shubham Pant, David R. Spigel, Nataliya V. Uboha, Paul E. Oberstein, Anwaar Saeed, Ji Kim, Ning WANG, Ben Weeder, Karim Mrouj, Jennifer Scott, Daniel DiRenzo, Matthew Walters, Wilson Wu, Soonweng Cho, Eileen M. O’Reilly, Brandon Beagle, Shravani Shitole, Lisa G. Ensign, Angelo Kaplan, Omar Kabbarah
| Nature Verified
Abstract Quemliclustat potently inhibits CD73, a key enzyme producing immunosuppressive adenosine. In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
Open in Who Shared Issue with article?
See all 3 articles